http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007127809-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d8997d30ef988d43885f716f01df7500
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-06
filingDate 2007-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afa63d6156143fee89ecbcfe252d8ba6
publicationDate 2008-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2007127809-A3
titleOfInvention P8 modulation to control hypertension
abstract The instant invention features several methods for treating hypertension. One such method features treating hypertension by a method including the step of administering to a patient, or a subject in need of such a treatment, an agonist, or an antagonist, of internalization of AT1 receptor after the AT1 receptor has bound angiotensin II. The instant invention also features a method for modulating the activity of an AT1 receptor by contacting the AT1 receptor with p8, a fragment of p8, or a functional derivative of p8. In particular embodiments, the AT1 receptor is contacted by a compound that modulates the interaction between the AT1 receptor and p8. In other particular embodiments, the contact between the AT1 receptor with p8, a fragment of p8, or a functional derivative of p8 occurs intracellularly.
priorityDate 2006-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003087306-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394001
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID172198

Total number of triples: 16.